Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

NCT ID: NCT05423327

Last Updated: 2023-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

5311 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-09

Study Completion Date

2022-10-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-alcoholic Steatohepatitis (NASH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

N/A: No study drug administered
Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Blood Draw

Group Type OTHER

No Intervention

Intervention Type PROCEDURE

Single blood draw

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention

Single blood draw

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

One or more of the following:

1. A prior diagnosis of NASH with a Clinical Research Network (CRN) fibrosis score of F1 to F4 based on liver biopsy
2. Evidence of NAFLD by imaging or liver histology as described in the protocol

* The possible imaging modalities to assess historic evidence of NAFLD may be based on thresholds as described in the protocol
3. Known high-risk genotype for HSD17B13 (T/T or T/TA) and/or PNPLA3 (C/G,or G/G)
4. A clinical suspicion of NASH based on presence of 2 or more elements of the metabolic syndrome defined by:

1. Waistline that measures \>35 inches (89 centimeters) for women or \>40 inches (102 centimeters) for men
2. Historic fasting triglycerides \>150 mg/dL within the prior 6 months
3. Historic fasting HDL cholesterol \<40 mg/dL in men or \<50 mg/dL in women, or on cholesterol-lowering medication within the prior 6 months
4. Historic fasting blood glucose \>100 mg/dL or on diabetes medication within the prior 6 months
5. Historic blood pressure \>130/85 mmHg, or on anti-hypertensive medication within the prior 6 months

Exclusion Criteria

1. Known history or clinical evidence of drug abuse, within the 12 months before screening. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms.
2. Excessive alcohol intake for ≥3 months during the past year prior to screening (\>3 units/day for males and \>2 units/day for females is generally considered excessive (unit: 1 glass of wine \[approximately 125 mL\]=1 measure of spirits \[approximately 1 fluid ounce\]=½ pint of beer \[approximately 284 mL\]).
3. History of liver transplant, current placement on a liver transplant list, or Model for End-stage Liver Disease (MELD) score \>12.
4. History of viral and resolved hepatitis or human immunodeficiency virus (HIV).
5. Any malignancy within the past 5 years except for basal cell or squamous epithelial cell carcinoma of the skin, or any carcinoma in situ.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regeneron Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trial Management

Role: STUDY_DIRECTOR

Regeneron Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southern California Research Center

Coronado, California, United States

Site Status

Velocity Clinical Research

Gardena, California, United States

Site Status

UCSD Health System

La Jolla, California, United States

Site Status

National Research Institute

Los Angeles, California, United States

Site Status

Clinnova Research Solutions

Orange, California, United States

Site Status

National Research Institute

Panorama City, California, United States

Site Status

FEMZ Clinical Research

Redondo Beach, California, United States

Site Status

Inland Empire Liver Foundation

Rialto, California, United States

Site Status

Precision Research Institute, Llc

San Diego, California, United States

Site Status

San Fernando Valley Health Institute

West Hills, California, United States

Site Status

Integrity Clinical Research, LLC

Doral, Florida, United States

Site Status

Miami Clinical Research

Miami, Florida, United States

Site Status

Genoma Research Group, Inc.

Miami, Florida, United States

Site Status

US Associates in Research, LLC

Miami, Florida, United States

Site Status

Links Clinical Trials

Miami, Florida, United States

Site Status

Med Research Of Florida, LLC

Miami, Florida, United States

Site Status

Floridian Clinical Research

Miami Lakes, Florida, United States

Site Status

IMIC, Inc

Palmetto Bay, Florida, United States

Site Status

Revival Research

Palmetto Bay, Florida, United States

Site Status

Tandem Clinical Research, LLC

Marrero, Louisiana, United States

Site Status

Mercy Medical Center, Inc

Baltimore, Maryland, United States

Site Status

University of Pennsylvania - Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

Site Status

Mt. Olympus Medical Research

Friendswood, Texas, United States

Site Status

Mt. Olympus Medical Research

Houston, Texas, United States

Site Status

Synergy Group US LLC

Houston, Texas, United States

Site Status

Pioneer Research Solutions, Inc

Houston, Texas, United States

Site Status

Liver Center of Texas

Plano, Texas, United States

Site Status

Epic Medical Research

Red Oak, Texas, United States

Site Status

American Research Corporation at The Texas Liver Institute

San Antonio, Texas, United States

Site Status

R & H Clinical Research

Stafford, Texas, United States

Site Status

Centro de Diabetes de Curitiba Ltda

Curitiba, Paraná, Brazil

Site Status

Hospital de Clínicas de Porto Alegre (HCPA)

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

IBPClin-Instituto Brasil de Pesquisa Clínica - CCBR

Rio de Janeiro, , Brazil

Site Status

Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo

São Paulo, , Brazil

Site Status

Grupo Médico Terranova - Hospital Terranova

Guadalajara, Jalisco, Mexico

Site Status

CEDOPEC - Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiovasculares, S.C.

Miguel Hidalgo, Mexico City, Mexico

Site Status

PCR

Cuautitlán Izcalli, State of Mexico, Mexico

Site Status

Unidad de Atención Médica e Investigación en Salud (UNAMIS)

Mérida, Yucatán, Mexico

Site Status

Investigación en Salud y Metabolismo S.C / Nutrición Clínica

Chihuahua City, , Mexico

Site Status

Dr. Federico Rodriguez-Perez MD, Office of

San Juan, , Puerto Rico

Site Status

Latin Clinical Trial Center

San Juan, , Puerto Rico

Site Status

VA Caribbean Healthcare System

San Juan, , Puerto Rico

Site Status

Fundación de Investigación de Diego, Inc.

San Juan, , Puerto Rico

Site Status

Dr. Paola Mansilla-Letelier MD, Office of

San Juan, , Puerto Rico

Site Status

Keimyung University Dongsan Hospital

Dalseo-gu, Daegu, South Korea

Site Status

Seoul National University College of Medicine, Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Hanyang University Seoul Hospital

Seoul, Gyeonggi-do, South Korea

Site Status

Chung-Ang University Hospital

Dongjak-gu, Seoul, South Korea

Site Status

Seoul National University Hospital

Jongno-gu, Seoul, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Brazil Mexico Puerto Rico South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R0000-NASH-CES-2117

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Reverse Phenotyping Core
NCT03632239 ENROLLING_BY_INVITATION
Genetic Collection Protocol
NCT05272319 RECRUITING
Rare and Undiagnosed Disease Research Biorepository
NCT04703179 ENROLLING_BY_INVITATION
Finding Genes for Rare Diseases
NCT02724995 WITHDRAWN